The invention described herein relates to methods and compositions for treatment of one or more symptoms of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity) by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.

The invention provides protease genes which are regulated in a specific manner during curing of tobacco plants material and which affect the flavour of cured tobacco.

The present disclosure provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a biological macromolecule comprising one or more thiol groups; and (b) a molecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure also provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a molecule comprising one or more thiol groups; and (b) biological macromolecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure further provides a covalently modified biological macromolecule prepared by any of disclosed methods. The covalently modified biological macromolecules may be further crosslinked to form a scaffold.

The present invention relates to a genetically modified plant or plant cell derived from a wild-type plant or plant cell, said wild-type plant or plant cell producing at least one serine protease comprising the motif SSRGPX.sub.1LKPDX.sub.2X.sub.3APGX.sub.4SGTSMSCPHX.sub.5PX.sub.6WSPX.sub.7AX.sub.8X.sub.9SAX.sub.10MTT (SEQ ID No. 1), wherein

X.sub.1 is a peptide consisting of 7 amino acid residues, X.sub.2 is I or L, X.sub.3 is T or M, X.sub.4 is a peptide consisting of 27 or 28 amino acid residues, X.sub.5 is a peptide consisting of 12 amino acid residues, X.sub.6 is T or E, X.sub.7 is S or A, X.sub.8 is V or I, X.sub.9 is K or R and X.sub.10 is I or M, wherein the proteolytic activity of the at least one serine protease in the genetically modified plant or plant cell is reduced compared to its activity in the wild-type plant or plant cell, wherein the genetically modified plant or plant cell comprises at least one exogenous nucleic acid molecule encoding for at least one protein or polypeptide of interest.

This invention disclosed herein relates generally to compositions comprising the cysteine protease ananain, a reducing agent and a buffer. Also disclosed generally herein are methods of stabilizing the cysteine protease, ananain while retaining protease activity, as well as methods of activating ananain zymogen for proteolysis.

Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori. Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.

The present disclosure provides methods to identify peptides and small molecule moieties that are able to functionally bridge an interaction between a target protein and an E3 ubiquitin ligase to mediate the degradation of the target protein. Some moieties can degrade specific target variants, but not others. The moieties create a neosubstrate for an E3 ligase of interest. The methods described enable generation of compounds able to selectively degrade specific targets within cells with implications for drug development for pathological conditions. The disclosure also describes the generation of modified peptides using post-translational modification enzymes, such as N-methyltransferases, prolyloligopeptidases, lactamases, hydroxylases, and dehydratases, along with methods of using the same.

The present invention relates to debriding compositions in the form of an aqueous gel. Particularly, the present invention relates to a debriding composition comprising a proteolytic enzyme mixture obtained from bromelain present in a dry form, and an aqueous gel carrier, wherein, prior to use, the proteolytic enzyme mixture being admixed with the aqueous gel carrier to form a debriding composition useful for debridement and treatment of c wounds.

The present invention relates to a method for isolating and culturing neural stem cells with high efficiency, which may shorten the time for isolation and culture by simplifying a method for isolating and culturing neural stem cells and may increase the acquisition yield of neural stem cells. The present invention provides a method for isolating and culturing neural stem cells with high efficiency, comprising the steps of adding brain tissue into an enzyme solution so as to subject the brain tissue to enzyme treatment; physically isolating cell clumps from the enzyme treated brain tissue by dividing the cell clumps according to size and removing impurities; and inoculating the cell clumps on a culture dish so as to subculture.

The present invention lies in the technical field of enzyme technology and specifically relates to enzymes having Asx-specific ligase and cyclase activity and to nucleic acids encoding those as well as methods of the manufacture of said enzymes. The enzymes having Asx-specific ligase and cyclase are isolated from plants of the Violaceae family. Further encompassed are methods and uses of these enzymes.